Kristofor Webb

Under the DARPA SPARTA program, I developed an innovative proteomic mass spectrometry platform with capabilities for small molecule early exploratory target identification. This technology is ideal for target identification in a drug discovery pipeline. Relevant methodologies include the identification of novel targets, small molecule target deconvolution, direct protein substrate identification and characterization, protein post-translation modification studies, and small molecule-protein interactome analyses. General understanding of target deconvolution methods including iTSA, CETSA, DARTS, and chemical probes/proteomics. Experience and knowledge in the operation and maintenance of different types of mass spectrometers including Q Exactive Hybrid Quadrupole and Orbitrap Fusion Tribrid. Extensive knowledge and application of complex sample preparation methodologies as applied to protein mass spectrometry workflows. Ability to characterize protein post-translational modifications including phosphorylation, methylation, acetylation, and ubiquitination. Expertise in implementing quantitative mass spectrometry-based strategies including isotopic labeling, isobaric tagging (TMT), SILAC, and label-free analysis (DIA, PRM/SRM) methods. Applied knowledge with MS software analysis pipelines including IP2, Proteome Discoverer, MaxQuant, and Skyline. General understanding of chemical proteomics methodologies including affinity enrichment. Ability to script in the R language for statistical analysis, data cleaning, and the detection of batch effects. I have the ability to complete and effectively manage multiple projects within timelines ensuring that all tasks and responsibilities are carried out according to high scientific and ethical standards.